VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NEUP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NEUPNeuphoria Therapeutics Inc.
$2.28$12M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
NEUP logo

Neuphoria Therapeutics Inc.

NEUP
NASDAQ · Neuroscience Biotech
$2.28
At close - Nov 18, 4:00 PM EST - USD
Market Cap$12M
P/E-2.5x
52W High$5.53
Volume24.22K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Volatile Licensing Revenue Masks Clinical Burn Risks

Neuphoria Therapeutics operates as a high-risk, pre-revenue clinical entity whose financial stability is entirely contingent upon sporadic, non-recurring licensing milestones rather than sustainable commercial operations.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

NEUP price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

3/12 Beats

EPS beat 3 of last 12 quarters

02

Valuation risk

-107% Peers

P/E is 107% below peer median

03

Market leadership

RS 17 · Lag

Laggard (Underperforming 83% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Dec 18

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
NEUP-40.31%
S&P 500 (^GSPC)+6.88%
1-Year Return
NEUP-51.90%
S&P 500 (^GSPC)+10.62%
3-Year Return
NEUP-90.64%
S&P 500 (^GSPC)+58.19%
5-Year Return
NEUP-98.71%
S&P 500 (^GSPC)+55.72%

Growth & profitability

Annual revenue & EPS trend
Revenue FY26
$1M-92.5% YoY
Net income FY26
-$13M-3539.3% YoY
Free cash flow FY26
-$12M-116.0% YoY
Operating margin FY26
-835.5%-828.3 pts YoY
ROIC (FY26)-0.1%
Avg ROIC 5Y-123.5%
ROE (TTM)-18.5%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate3/12 (30%)
Revenue Beat Rate2/12 (33%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Sep 18, 2026
-$0.56+0.0%
vs -$0.56
$1M+17.4%
vs $996,483
Q4 2026
Sep 2, 2026
-$0.56+0.0%
vs -$0.56
$1M+0.0%
vs $1M
Q2 2026
May 15, 2026
-$0.09+83.9%
vs -$0.56
—
vs —
Q1 2026
Feb 17, 2026
-$0.77-37.5%
vs -$0.56
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
04

Compare before deciding

Benchmark NEUP against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Neuphoria Therapeutics Inc. (NEUP)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NEUP logoNEUPNeuphoria Therapeutics Inc.Current
$2.28$12.32M-2.48-92.5%-423.32%-18.55%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$17.83$3.05B8.6411.87%30.13%28.03%—
INVA logoINVAInnoviva, Inc.
$18.40$1.36B6.8618.52%43.79%15.84%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.19$8.51B-24.78-100%—-29.41%—
BIIB logoBIIBBiogen Inc.
$251.41$37.15B106.781.39%3.38%1.86%—
ALKS logoALKSAlkermes plc
$46.85$7.86B-9999.00-5.25%-0.02%-0.02%—

Compare NEUP vs Peers

Neuphoria Therapeutics Inc. (NEUP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ACAD

Most directly comparable listed peer for NEUP.

Scale Benchmark

vs MRNA

Larger-name benchmark to compare NEUP against a more recognizable public peer.

Peer Set

Compare Top 5

vs ACAD, INVA, PRAX, BIIB

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

NEUP SEC Filings & Documents

Neuphoria Therapeutics Inc. (NEUP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 23, 2026·SEC

Material company update

May 26, 2026·SEC

Material company update

Jan 8, 2026·SEC

10-K Annual Reports

3
FY 2026

Sep 18, 2026·SEC

FY 2025

Sep 29, 2025·SEC

FY 2024

Sep 30, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 15, 2026·SEC

FY 2026

Feb 17, 2026·SEC

FY 2025

Nov 14, 2025·SEC

Get notified when NEUP posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NEUP Frequently Asked Questions

Neuphoria Therapeutics Inc. (NEUP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Neuphoria Therapeutics Inc.'s revenue?

Neuphoria Therapeutics Inc. (NEUP) reported $1.2M in revenue in fiscal year 2026, which is also its trailing twelve months.

How fast is Neuphoria Therapeutics Inc. growing?

Neuphoria Therapeutics Inc. (NEUP) revenue fell by 77.4% over the trailing twelve months, compared with the twelve months before.

Is NEUP profitable?

No. Neuphoria Therapeutics Inc. (NEUP) reported a net loss of $5.0M over the trailing twelve months.

Dividend & Returns
What is NEUP's return on equity?

Neuphoria Therapeutics Inc. (NEUP) had a return on equity (ROE) of -18.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Neuphoria Therapeutics Inc.'s free cash flow?

Neuphoria Therapeutics Inc. (NEUP) had negative free cash flow of $9.7M over the trailing twelve months.

What if you invested $1,000 in NEUP back in 1999?

Total return calculator · dividends reinvested · 27+ years of data

See returns →